Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 181: The study dealing with the effect of drugs on the body is known as:

A. Pharmacokinetics.
B. Pharmacodynamics. (Correct Answer)
C. Drug kinetics.
D. None.

Explanation: ### Explanation **Pharmacodynamics** is the correct answer because it describes **"what the drug does to the body."** It focuses on the biochemical and physiological effects of drugs and their mechanisms of action. This includes drug-receptor interactions, dose-response relationships, and the resulting therapeutic or toxic effects. The term is derived from the Greek words *pharmakon* (drug) and *dynamis* (power). **Analysis of Incorrect Options:** * **Pharmacokinetics:** This refers to **"what the body does to the drug."** It involves the quantitative study of drug movement through the body, specifically the processes of **ADME**: Absorption, Distribution, Metabolism, and Excretion. * **Drug kinetics:** This is a general term often used interchangeably with pharmacokinetics, specifically focusing on the rates of drug movement and elimination (e.g., zero-order or first-order kinetics). It does not describe the drug's effect on the body. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic:** Remember **D** for **D**ynamics = **D**rug’s action; **K** for **K**inetics = Movement (**K**inetic energy). * **Key Parameters:** Pharmacodynamics deals with **Efficacy** (Emax) and **Potency** (EC50), whereas Pharmacokinetics deals with **Bioavailability, Volume of Distribution (Vd), and Half-life (t½).** * **Receptor Regulation:** A crucial part of pharmacodynamics is understanding **Down-regulation** (seen in chronic agonist use, e.g., Salbutamol in asthma) and **Up-regulation** (seen in chronic antagonist use, e.g., Propranolol).

Question 182: Which of the following is a Cytochrome P450 inhibitor?

A. Ketoconazole (Correct Answer)
B. Rifampicin
C. Phenytoin
D. None of the above

Explanation: **Explanation:** The correct answer is **Ketoconazole**. This question tests the fundamental pharmacological concept of drug-metabolizing enzyme modulation, specifically the Cytochrome P450 (CYP450) system. **1. Why Ketoconazole is correct:** Ketoconazole is a potent **enzyme inhibitor** [1], [2], [3]. It binds to the iron atom of the heme group in CYP450 enzymes (specifically CYP3A4), preventing the oxidation of other drugs [1]. This leads to decreased metabolism and increased plasma concentrations of co-administered drugs (e.g., Warfarin, Statins), potentially leading to toxicity [2]. **2. Why the other options are incorrect:** * **Rifampicin:** This is a classic, potent **enzyme inducer** [2]. It increases the synthesis of CYP450 enzymes, leading to faster metabolism and reduced efficacy of co-administered drugs (e.g., Oral Contraceptive Pills, leading to contraceptive failure). * **Phenytoin:** This is also a well-known **enzyme inducer**. Like Rifampicin, it accelerates the clearance of other drugs metabolized by the liver. **3. High-Yield Clinical Pearls for NEET-PG:** To remember these for the exam, use these popular mnemonics: * **Enzyme Inhibitors (VITAMINS K):** **V**alproate, **I**soniazid, **T**rimethoprim, **A**miodarone, **M**acrolides (except Azithromycin), **I**ndinavir, **N**etilmicin (and other Azoles like **Ketoconazole**), **S**ulfonamides, **C**imetidine, **G**rapefruit juice. * **Enzyme Inducers (GPRS Cell Phone):** **G**riseofulvin, **P**henytoin, **R**ifampicin, **S**moking, **C**arbamazepine, **P**henobarbitone. **Key Fact:** Ketoconazole is also known to inhibit steroid synthesis (adrenal and gonadal) [1], [3], which is why it can cause side effects like gynecomastia in males.

Question 183: Which drug is not acetylated?

A. Isoniazid
B. Dapsone
C. Hydralazine
D. Metoclopramide (Correct Answer)

Explanation: **Explanation:** The question tests your knowledge of **Phase II metabolic reactions**, specifically **Acetylation**. This process is mediated by the enzyme **N-acetyltransferase (NAT)** in the liver. **Why Metoclopramide is the correct answer:** Metoclopramide is a prokinetic and antiemetic drug that primarily undergoes **Glucuronidation** and **Sulfate conjugation** (Phase II) and some oxidation (Phase I). It is not metabolized via the acetylation pathway. **Why the other options are incorrect:** Options A, B, and C are classic examples of drugs that undergo acetylation. A high-yield mnemonic to remember these is **"SHIP"**: * **S – Sulfonamides** (and **Dapsone**, which is a related sulfone) * **H – Hydralazine** * **I – Isoniazid (INH)** * **P – Procainamide** **Clinical Pearls for NEET-PG:** 1. **Genetic Polymorphism:** Acetylation exhibits "bimodal distribution" in the population, dividing individuals into **Fast Acetylators** and **Slow Acetylators**. 2. **Slow Acetylators:** These individuals have a deficiency of the NAT enzyme. They are at a higher risk of drug-induced toxicities, such as: * **Peripheral Neuropathy** with Isoniazid (due to Vitamin B6 deficiency). * **Drug-Induced Lupus Erythematosus (DILE)** with Hydralazine, Procainamide, and Isoniazid. 3. **Fast Acetylators:** They require higher doses of these drugs to achieve therapeutic levels and are more prone to **Hepatotoxicity** with Isoniazid (due to rapid conversion to the toxic metabolite acetylhydrazine).

Question 184: Chloroquine is given as a 600 mg loading dose because?

A. It is rapidly absorbed.
B. It is rapidly metabolized.
C. It has increased tissue binding. (Correct Answer)
D. It is rapidly eliminated.

Explanation: ### Explanation The correct answer is **C. It has increased tissue binding.** #### 1. Why the Correct Answer is Right The primary reason for giving a loading dose of Chloroquine is its **exceptionally large Volume of Distribution ($V_d$)**. Chloroquine exhibits extensive tissue binding; it accumulates in high concentrations in the liver, spleen, kidneys, lungs, and particularly in melanin-containing tissues like the retina. In pharmacokinetics, if a drug has a high $V_d$, it takes a long time to reach the **steady-state plasma concentration** because the drug first distributes into the tissues (the "peripheral compartment"). To achieve immediate therapeutic levels in the blood and saturate these tissue stores, a **loading dose** is required. Without it, the drug would take weeks to reach effective levels. #### 2. Why the Other Options are Wrong * **A. Rapidly absorbed:** While Chloroquine is well-absorbed from the GI tract, rapid absorption does not necessitate a loading dose. Loading doses are about distribution and half-life, not the speed of entry into the body. * **B & D. Rapidly metabolized/eliminated:** These are incorrect because Chloroquine is actually **slowly eliminated**. It has a very long terminal half-life (30–60 days). Drugs that are rapidly eliminated usually require frequent dosing or continuous infusions, not necessarily a large initial loading dose to overcome tissue sequestration. #### 3. Clinical Pearls for NEET-PG * **Volume of Distribution ($V_d$):** Chloroquine has one of the highest $V_d$ values in pharmacology (approx. 13,000 L). * **Mechanism of Action:** It inhibits the enzyme **heme polymerase**, leading to the accumulation of toxic heme (ferriprotoporphyrin IX) which kills the parasite. * **Adverse Effects:** High tissue binding in the retina leads to **"Bull’s eye maculopathy"** (permanent retinal damage). * **Loading Dose Formula:** $LD = V_d \times \text{Target Plasma Concentration}$. This formula highlights that $LD$ is directly proportional to $V_d$.

Question 185: Which of the following substances can cross the blood-brain barrier?

A. Dopamine
B. Propranolol
C. Glycopyrrolate
D. Physostigmine (Correct Answer)

Explanation: **Explanation:** The ability of a drug to cross the **Blood-Brain Barrier (BBB)** depends primarily on its lipid solubility and ionization state. To penetrate the CNS, a molecule must be **lipophilic** and **non-ionized**. **Why Physostigmine is Correct:** Physostigmine is a **tertiary amine** anticholinesterase. Unlike quaternary compounds, tertiary amines are uncharged (non-ionized) and highly lipid-soluble, allowing them to readily cross the BBB. This makes Physostigmine the drug of choice for treating central anticholinergic toxicity (e.g., Atropine poisoning). **Analysis of Incorrect Options:** * **Dopamine (A):** Although it is a neurotransmitter, dopamine is highly polar and does not cross the BBB. This is why **Levodopa** (a precursor that uses a transport carrier) is used in Parkinson’s disease instead of dopamine itself. * **Propranolol (B):** *Note: Propranolol actually DOES cross the BBB due to its high lipophilicity (causing side effects like vivid dreams).* However, in the context of this specific question format comparing it to the definitive "tertiary vs. quaternary" pharmacological principle of Physostigmine, Physostigmine is the classic textbook answer for "crossing the BBB" in cholinergic pharmacology. * **Glycopyrrolate (C):** This is a **quaternary ammonium** compound. It is permanently charged (ionized), making it lipid-insoluble and unable to cross the BBB. It is used when peripheral anticholinergic effects are desired without CNS side effects. **NEET-PG High-Yield Pearls:** 1. **Tertiary Amines (Cross BBB):** Physostigmine, Atropine, Scopolamine, Rivastigmine. 2. **Quaternary Amines (Do NOT cross BBB):** Neostigmine, Pyridostigmine, Edrophonium, Glycopyrrolate. 3. **Clinical Rule:** Use **Physostigmine** for Atropine poisoning (Central + Peripheral symptoms); use **Neostigmine** for Myasthenia Gravis (Peripheral action only).

Question 186: A patient reaches a steady state level of lithium that produces toxic side effects. If he decides to discontinue his medication, how long would it take for his lithium blood levels to reach 25% of his original steady state levels, assuming a half-life of 22 hours for lithium?

A. 11 hours
B. 22 hours
C. 33 hours
D. 44 hours (Correct Answer)

Explanation: ### Explanation **1. Understanding the Correct Answer (D: 44 hours)** The elimination of drugs following **first-order kinetics** (like Lithium) occurs at a constant fractional rate. The time required for the plasma concentration of a drug to reduce by 50% is defined as its **half-life ($t_{1/2}$)**. To reach 25% of the steady-state concentration, the drug must undergo **two half-lives**: * **After 1st half-life:** Concentration drops to 50% of the original level. * **After 2nd half-life:** Concentration drops to 25% (half of 50%). Given the $t_{1/2}$ of Lithium is 22 hours: $2 \times 22 \text{ hours} = \mathbf{44 \text{ hours}}$. **2. Analysis of Incorrect Options** * **Option A (11 hours):** This represents half of a half-life ($0.5 \times t_{1/2}$), which does not correspond to a standard elimination milestone. * **Option B (22 hours):** This is exactly one half-life. At this point, the concentration would be 50%, not 25%. * **Option C (33 hours):** This represents 1.5 half-lives. At this stage, the concentration would be approximately 35.3%. **3. Clinical Pearls for NEET-PG** * **Steady State Rule:** It takes approximately **4 to 5 half-lives** to reach steady-state concentration ($C_{ss}$) and the same amount of time to completely eliminate a drug from the body (>95% washout). * **Lithium Kinetics:** Lithium is handled by the kidneys similarly to sodium. Dehydration, NSAIDs, and Thiazide diuretics can decrease its clearance, leading to toxicity. * **Therapeutic Index:** Lithium has a **narrow therapeutic index** (0.6–1.2 mEq/L). Toxicity typically manifests at levels >1.5 mEq/L with symptoms like coarse tremors, ataxia, and seizures. * **First-Order vs. Zero-Order:** Most drugs follow first-order kinetics (constant percentage per unit time). Only a few follow zero-order (constant amount per unit time), such as **P**henytoin, **A**lcohol, and **W**arfarin/High-dose **A**spirin (Mnemonic: **PAW**).

Question 187: A drug has 80% absorption and a hepatic extraction ratio of 0.4. Calculate the bioavailability of the drug?

A. 12%
B. 32%
C. 48% (Correct Answer)
D. 64%

Explanation: ### Explanation **1. Understanding the Correct Answer (C: 48%)** Bioavailability ($F$) is the fraction of an administered dose that reaches the systemic circulation in an unchanged form. When a drug is given orally, it must first be absorbed from the gut and then pass through the liver (first-pass metabolism). The formula for systemic bioavailability is: **$F = f \times (1 - ER)$** * **$f$ (Absorption):** 80% or 0.8 * **$ER$ (Extraction Ratio):** 0.4 * **$(1 - ER)$ (Hepatic Escape Fraction):** This represents the fraction of the drug that escapes hepatic metabolism. Here, $1 - 0.4 = 0.6$ (or 60%). **Calculation:** $F = 0.8 \times 0.6 = 0.48$ $0.48 \times 100 = \mathbf{48\%}$ **2. Why Other Options are Incorrect** * **A (12%):** This is a mathematical error, likely from multiplying half of the extraction ratio by a fraction of the absorption. * **B (32%):** This occurs if you incorrectly multiply the absorption (0.8) by the extraction ratio (0.4) instead of the escape fraction. This represents the amount metabolized, not the amount reaching circulation. * **D (64%):** This value is obtained if one ignores the extraction ratio and applies a different coefficient, or incorrectly calculates $0.8 \times 0.8$. **3. NEET-PG High-Yield Clinical Pearls** * **Definition:** Bioavailability of an **Intravenous (IV)** dose is always **100% (F=1)**. * **First-Pass Effect:** Drugs with a high Hepatic Extraction Ratio (e.g., **Lidocaine, Propranolol, Nitroglycerin**) have low oral bioavailability and are often given via non-enteral routes. * **Area Under the Curve (AUC):** Bioavailability is calculated by comparing the AUC of oral administration to the AUC of IV administration: $F = \frac{AUC_{oral}}{AUC_{IV}}$. * **Clinical Significance:** If a drug’s ER is >0.7, its bioavailability will be low, and small changes in hepatic enzyme activity can lead to significant changes in plasma drug levels.

Question 188: Which pathological state alters the volume of distribution of many drugs?

A. Septicemia
B. Duodenal ulcers
C. Congestive heart failure (Correct Answer)
D. Hypertension

Explanation: **Explanation:** **Volume of Distribution ($V_d$)** is a theoretical volume that relates the amount of drug in the body to its plasma concentration. It is significantly influenced by cardiac output, tissue perfusion, and fluid balance. **Why Congestive Heart Failure (CHF) is correct:** In CHF, the heart's pumping capacity is compromised, leading to several physiological changes that alter $V_d$: 1. **Decreased Tissue Perfusion:** Reduced cardiac output leads to poor perfusion of peripheral tissues (skeletal muscle, adipose), decreasing the $V_d$ for drugs that normally distribute into these compartments (e.g., Lidocaine). 2. **Edema and Effusions:** Conversely, for water-soluble drugs (e.g., Aminoglycosides), the presence of peripheral edema or ascites can *increase* the $V_d$. 3. **Organ Congestion:** Hepatic and renal congestion can impair drug clearance, further complicating the pharmacokinetic profile. **Why the other options are incorrect:** * **Septicemia:** While severe sepsis (septic shock) can alter $V_d$ due to capillary leak, CHF is the classic, more frequently tested pathological state in standard pharmacology for altering $V_d$ via systemic perfusion changes. * **Duodenal Ulcers:** This is a localized gastrointestinal pathology. It may affect the *absorption* of certain drugs but does not typically alter the systemic volume of distribution. * **Hypertension:** Most patients with primary hypertension have normal cardiac output and fluid status; therefore, $V_d$ remains largely unchanged unless hypertensive heart failure or renal failure develops. **High-Yield Clinical Pearls for NEET-PG:** * **Loading Dose Calculation:** $Loading\ Dose = V_d \times Target\ Plasma\ Concentration$. In CHF, loading doses of drugs like **Digoxin** or **Lidocaine** often need adjustment. * **Plasma Protein Binding:** Conditions like Uremia or Hypoalbuminemia (Liver Cirrhosis) also significantly alter $V_d$ by increasing the "free" fraction of drugs. * **Vd > 42L:** Indicates the drug is sequestered in tissues (e.g., Chloroquine, Digoxin) and cannot be removed by hemodialysis.

Question 189: In hepatic metabolism, which of the following are considered Phase II reactions?

A. Sulfation
B. Methylation
C. Glucuronidation
D. All of these (Correct Answer)

Explanation: Drug metabolism (biotransformation) primarily occurs in the liver and is divided into two phases [1], [2]. **Phase II reactions** are conjugation reactions where an endogenous hydrophilic group is attached to a drug or its Phase I metabolite [1], [2]. This process significantly increases the water solubility of the drug, facilitating its excretion through urine or bile [1], [2]. **Explanation of Options:** * **Glucuronidation:** This is the most common and important Phase II reaction [1], [2]. It utilizes the enzyme UDP-glucuronosyltransferase (UGT) [2]. * **Sulfation:** This involves the transfer of a sulfate group to phenols or alcohols, catalyzed by sulfotransferases (SULTs) [1], [2]. * **Methylation:** While less common, it is a vital Phase II pathway for drugs like L-Dopa and catecholamines, catalyzed by methyltransferases (e.g., COMT) [1], [2]. * **Other Phase II reactions** include Acetylation (catalyzed by NAT) and Glutathione conjugation [1], [2]. Since Sulfation, Methylation, and Glucuronidation are all conjugation processes that render drugs more polar, **Option D** is the correct answer. **Why other options are not "the only" answer:** Options A, B, and C are individual components of Phase II metabolism. Selecting any one would be incomplete, as all three belong to the same category. **High-Yield Clinical Pearls for NEET-PG:** * **Phase I Reactions:** Include Oxidation (most common, via CYP450), Reduction, and Hydrolysis [1], [2]. They usually introduce or expose a functional group (-OH, -NH2, -SH) [2]. * **Exception to the Rule:** Most Phase II reactions terminate biological activity. However, **Morphine-6-glucuronide** is a Phase II metabolite that is *more* potent than morphine itself. * **Neonatal Physiology:** Neonates are deficient in glucuronidation, leading to **Gray Baby Syndrome** when treated with Chloramphenicol. * **Acetylation Polymorphism:** Isoniazid, Hydralazine, and Procainamide are metabolized by acetylation; "slow acetylators" are at higher risk of drug-induced lupus.

Question 190: Which of the following statements about biotransformation is untrue?

A. Inactive metabolites are formed.
B. Active metabolites are formed.
C. More fat-soluble metabolites are formed. (Correct Answer)
D. More water-soluble metabolites are formed.

Explanation: ### Explanation **Biotransformation** (Drug Metabolism) is the chemical alteration of a drug in the body, primarily occurring in the liver. Its fundamental biological purpose is to convert **lipid-soluble (non-polar)** compounds into **water-soluble (polar)** compounds to facilitate excretion by the kidneys. #### Why Option C is Untrue (The Correct Answer) Metabolism aims to decrease lipid solubility. If metabolites were more fat-soluble, they would be reabsorbed by the renal tubules back into the systemic circulation, leading to drug accumulation and toxicity. Therefore, the formation of more fat-soluble metabolites is incorrect. #### Analysis of Other Options * **A & B: Inactive and Active metabolites are formed:** Most drugs are inactivated by metabolism (e.g., Paracetamol). However, some drugs are converted into **active metabolites** (e.g., Diazepam to Oxazepam) or are administered as **Prodrugs** (e.g., Enalapril to Enalaprilat), where metabolism is required for activation. * **D: More water-soluble metabolites are formed:** This is the primary goal of Phase I (Functionalization) and Phase II (Conjugation) reactions. Increasing polarity ensures the drug can be easily excreted in urine or bile. #### NEET-PG High-Yield Pearls * **Phase I Reactions:** Include Oxidation (most common), Reduction, and Hydrolysis. These primarily involve the **Cytochrome P450** enzyme system. * **Phase II Reactions:** Include Glucuronidation (most common), Acetylation, and Methylation. These usually result in total inactivation. * **Exception to the Rule:** Morphine-6-glucuronide is a rare example of a Phase II metabolite that is *more* active than the parent drug. * **First-Pass Metabolism:** Drugs with high first-pass metabolism (e.g., Nitroglycerin, Lidocaine) have low oral bioavailability.

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free